Harnessing programmed death-ligand 1 as a prognostic marker in OSCC: Challenges and opportunities in the era of immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Harnessing programmed death-ligand 1 as a prognostic marker in OSCC: Challenges and opportunities in the era of immunotherapy

Published:2024-09 Issue: Volume:11 Page:100641
ISSN:2772-9060
Container-title:Oral Oncology Reports
language:en
Short-container-title:Oral Oncology Reports

Author:

Krishnan Madhan^ORCID,Babu Shyamaladevi

Publisher

Elsevier BV

Reference8 articles.

1. Oral cavity squamous cell carcinoma: an update of the pharmacological treatment;Imbesi Bellantoni;Biomedicines,2023

2. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment;Parvez;Front Immunol,2023

3. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges;Javed;Front Immunol,2024

4. Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer;Jiang;Front Immunol,2022

5. PD-L1 in oral squamous cell carcinoma: a key biomarker from the laboratory to the bedside;Nocini;Clin Exp Dent Res,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP